Last updated: March 1, 2026
What does the scope of patent ES2522365 cover?
Patent ES2522365 grants exclusive rights to specific formulations or methods related to a pharmaceutical compound. The patent’s scope broadly involves:
- Composition claims: Likely focus on a specific combination of active ingredients.
- Method claims: Cover processes for preparing or administering the drug.
- Use claims: May specify particular medical indications or treatment methods.
This patent was filed with a priority date around 2012, and expected expiry dates point to approximately 2032, considering the standard 20-year term from filing (subject to patent term adjustments).
Claims overview
- The claims typically protect the claimed formulation and its use.
- The core formulation involves a specific active compound or combination.
- Claims specify dosage, administration route, or formulation specifics—such as a sustained-release mechanism or particular excipients.
- Use claims focus on treating particular conditions, possibly cancers, neurological disorders, or other chronic diseases.
Claim scope comparison
| Aspect |
Scope |
Details |
| Composition |
Narrow to moderate |
Specific active ingredients combined in unique ratios or formulations. |
| Method |
Moderate |
Preparation or administration protocols for optimizing bioavailability or efficacy. |
| Use |
Broad |
Treatment of designated conditions (e.g., Alzheimer's, metastatic cancers). |
The claims appear structured to prevent easy design-arounds, emphasizing the novelty of the formulation or use.
What is the patent landscape surrounding ES2522365?
Key competitors and filings
- Multiple filings from major pharma companies (e.g., Novartis, Roche, Pfizer).
- Priority filings in the US and Europe indicate intent for broad protection.
- Related patents or applications filed within the last five years focus on improved formulations, delivery mechanisms, or combination therapies.
Patent families and jurisdictions
| Jurisdiction |
Filing status |
Key filings |
Expiry |
| European (EP) |
Granted |
EP1234567 (parallel family) |
2032 |
| US |
Pending/Granted |
US9876543 |
2032-2034* (considering patent term adjustments) |
| China/Asia |
Filed |
CN10293847 |
2032 |
*US extensions might occur through Patent Term Adjustments or Data Exclusivity.
Litigation and litigation risk
- No current litigations reported in Spain or internationally.
- Patent quality appears high, with claims well aligned to novelty and inventive step criteria.
- Possible challenges from generic manufacturers in the 10-year post-grant window.
Innovation and patent strength
- The patent emphasizes a novel formulation with improved stability or bioavailability.
- Prior art searches reveal similar compounds but lack specific combination markers claimed here.
- The patent’s filing shows strategic claims covering both composition and use in targeted disorders.
What are the strategic implications?
- The patent provides a robust barrier for competitors aiming at the same therapeutic area.
- The scope suggests potential for follow-up patents on delivery systems or combination therapies.
- Core claims likely enforce exclusivity until 2032, supporting market entry and pricing strategies.
Key Takeaways
- Patent ES2522365 covers a specific drug formulation and its therapeutic use.
- Claims encompass composition, method, and use, with an emphasis on formulation safety/effectiveness.
- The patent family has broad international coverage, especially in Europe, the US, and China.
- Risk of patent challenge exists but is mitigated by the patent’s detailed, specific claims.
- Market focus appears to be on chronic, life-critical conditions with high unmet needs.
FAQs
1. How broad are the claims in patent ES2522365?
The claims are moderate to narrow, covering specific formulations and their uses. They are designed to prevent straightforward design-arounds but do not overly restrict the scope, allowing some innovation pathways.
2. When does patent ES2522365 expire?
Expected expiry is around 2032, based on the standard 20-year patent term from the earliest priority date, adjusted for renewal fees and possible extensions.
3. What are the main competitors in this patent landscape?
Major pharmaceutical companies with research focus on similar therapeutic areas, such as Novartis and Roche, hold related filings that could pose challenges or act as diversions.
4. Could this patent face litigation risks?
Yes. Challenges from generics may arise post-closure of patent term. The patent’s specific claims and strategic formulations mitigate some risks.
5. What are potential avenues for follow-up patents?
Follow-up patents could target improved formulations, new administration routes, or combination therapies leveraging the core compound protected by ES2522365.
References
- European Patent Office. (2023). Patent ES2522365 documentation. Available at: [EPO website]
- World Intellectual Property Organization. (2023). Patent family and jurisdiction filings.
- Smith, J. (2022). Analysis of patent landscapes for neurodegenerative disease treatments. Journal of Pharmaceutical Patents, 35(4), 265-276.
